2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2439

A Brief Exercise and Self Management Programme Improves Upper Limb Disability in People with Early Rheumatoid Arthritis
Abstract Number: 57

A British Survey of Time to Presentation and Treatment of Rheumatoid Arthritis in Subjects of Black and Minority Ethnic Origin
Abstract Number: 774

A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Abstract Number: 2250

A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis
Abstract Number: 1090

A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Replacement Patients
Abstract Number: 2243

A Comparison of Systemic Lupus Erythematosus (SLE) Patients Achieving Prolonged Clinical Quiescence (PCQ) On and off Corticosteroids and/or Immunosuppressive Medications
Abstract Number: 804

A Comparison of the Nociceptive Flexion Reflex, Pressure Algometry and Summated Widespread Pain in the Diagnosis of Fibromyalgia
Abstract Number: 1382

A Comparison of Three Methods of Measuring Intermalleolar Distance in Patients with Ankylosing Spondylitis
Abstract Number: 1987

A Comparison of Unilateral and Bilateral Hip BMD
Abstract Number: 1898

A Competence-Based Model for Teaching Rheumatology in Undergraduate Medical Students in Pontificia Universidad Católica De Chile: A Five Years Experience
Abstract Number: 1940

A Comprehensive Study of Novel Serum Markers of ILD Associated with Inflammatory Myopathies
Abstract Number: 136

A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria
Abstract Number: 1481

A Double-Blind Placebo-Controlled Crossover Trial of the Alpha-_2C Adrenoceptor Antagonist Orm-12741 for Prevention of Cold-Induced Vasospasm in Patients with Systemic Sclerosis
Abstract Number: 2619

A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Abstract Number: 861

A Family Based Pedometer Walking Program in an Adolescent Population with Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].